Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Numico CFO

This article was originally published in The Tan Sheet

Executive Summary

Jean-Marc Huet's selection as CFO, member of executive board will be proposed to shareholders during May 9 meeting, Dutch firm says Feb. 13. Announcement follows same-day statement that Royal Numico and current CFO Pim Oomens "are discussing his resignation"; further details were not released. Huet most recently "had co-responsibility" for Goldman Sachs' Netherlands office. Oomens had joined Numico in 1988 and became CFO in 2001. Management change follows a series of personnel shifts as Numico evaluates its U.S. operations (1"The Tan Sheet" Feb. 3, 2003, In Brief)...

You may also be interested in...



Numico personnel

Peter van Wel leaves company after serving under temporary contract as member of executive board responsible for U.S. operations, Dutch firm announces Jan. 30. Personnel change is part of Royal Numico's effort to "redefine the responsibilities of the U.S. management team" following firm's announcement it will divest Rexall Sundown (1"The Tan Sheet" Nov. 11, 2002, p. 3). Numico is looking for a successor with retail experience to focus on GNC, which was put on "probation" and could face divestiture if its financial performance does not improve. Van Well's successor also will be charged with executing the divestments...

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel